Leonard Zehr, Author at BioTuesdays

Markets

Analysts downgrade ContraFect after DSMB urges Phase 3 MRSA trial end

Analysts for SVB Securities and Maxim Group downgraded ContraFect (NASDAQ:CFRX) after a data safety monitoring board recommended termination for futility of a Phase 3 trial evaluating exebacase in methicillin-resistant...

July 14, 2022

Developments

Soricimed Biopharma receives additional investment from NBIF

Closely-held Soricimed Biopharma closed a $200,000 investment from the New Brunswick Investment Fund (NBIF) to continue developing its investigational SOR-13 oncology drug candidate. “We are grateful to NBIF for their...

July 13, 2022

Markets

Stifel cuts Atara Biotherapeutics to hold; PT to $5

Stifel downgraded Atara Biotherapeutics (NASDAQ:ATRA) to “hold” from “buy” and lowered its price target to $5 from $16, following the company’s interim Phase 2 analysis with ATA188 for the treatment of multiple...

July 13, 2022

Developments

Rhythm Pharma posts positive Phase 2 data in hypothalamic obesity

Rhythm Pharmaceuticals (NASDAQ:RYTM) reported positive interim results from a Phase 2 clinical trial evaluating setmelanotide, its MC4R agonist, for the treatment of severe obesity and hyperphagia in people living with...

July 12, 2022

Feature

TC Biopharm developing gamma-delta T-cells therapies for oncology

TC BioPharm (NASDAQ:TCBP) is a global leader in developing platform allogeneic gamma-delta T-cell therapies for cancer indications, with human efficacy data in acute myeloid leukemia (AML) and plans to expand into other...

July 12, 2022

Developments

Precigen to sell non-healthcare unit Trans Ova Genetics to URUS

Precigen (NASDAQ:PGEN) entered into a definitive agreement to sell its wholly-owned non-healthcare subsidiary, Trans Ova Genetics, an animal reproductive technologies company, to URUS, a holding company with cooperative...

July 5, 2022

Feature

Aristea Therapeutics in four clinical trials in rare inflammatory diseases

Closely-held Aristea Therapeutics is pursuing four rare inflammatory diseases with its oral, once-daily, small molecule drug candidate, RIST4721: palmoplantar pustulosis, familial Mediterranean fever, Behcet’s disease...

July 5, 2022

Developments

NeuroSense reports positive biomarker study in Alzheimer’s

NeuroSense Therapeutics (NASDAQ:NRSN) reported positive results from a biomarker study conducted to evaluate the potential of CogniC, NeuroSense’s combination drug for the treatment of Alzheimer’s disease...

June 30, 2022

Developments

Domain Therapeutics receives multimillion-dollar milestone from Merck

Domain Therapeutics, which operates in France and Canada, obtained a single-digit multimillion-dollar milestone payment from Merck as part of a €240 million collaboration and license partnership signed in 2017. Drug...

June 30, 2022

Feature

Pharvaris providing patient choice in developing oral treatments for hereditary angioedema

Pharvaris (NASDAQ:PHVS), a trans-Atlantic company, is developing two oral products to treat and prevent attacks in all subtypes of hereditary angioedema (HAE), with on-demand and prophylactic therapies.

June 28, 2022

Author - Leonard Zehr

Analysts downgrade ContraFect after DSMB urges Phase 3 MRSA trial end

Soricimed Biopharma receives additional investment from NBIF

Stifel cuts Atara Biotherapeutics to hold; PT to $5

Rhythm Pharma posts positive Phase 2 data in hypothalamic obesity

TC Biopharm developing gamma-delta T-cells therapies for oncology

Precigen to sell non-healthcare unit Trans Ova Genetics to URUS

Aristea Therapeutics in four clinical trials in rare inflammatory diseases

NeuroSense reports positive biomarker study in Alzheimer’s

Domain Therapeutics receives multimillion-dollar milestone from Merck

Pharvaris providing patient choice in developing oral treatments for hereditary angioedema

General

More